189 related articles for article (PubMed ID: 38321562)
1. Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment (HABIT) efficacy trial: Community health worker support may increase hydroxyurea adherence of youth with sickle cell disease.
Green NS; Manwani D; Aygun B; Appiah-Kubi A; Smith-Whitley K; Castillo Y; Soriano L; Jia H; Smaldone AM
Pediatr Blood Cancer; 2024 Apr; 71(4):e30878. PubMed ID: 38321562
[TBL] [Abstract][Full Text] [Related]
2. HABIT efficacy and sustainability trial, a multi-center randomized controlled trial to improve hydroxyurea adherence in youth with sickle cell disease: a study protocol.
Smaldone A; Manwani D; Aygun B; Smith-Whitley K; Jia H; Bruzzese JM; Findley S; Massei J; Green NS
BMC Pediatr; 2019 Oct; 19(1):354. PubMed ID: 31615480
[TBL] [Abstract][Full Text] [Related]
3. Randomized feasibility trial to improve hydroxyurea adherence in youth ages 10-18 years through community health workers: The HABIT study.
Green NS; Manwani D; Matos S; Hicks A; Soto L; Castillo Y; Ireland K; Stennett Y; Findley S; Jia H; Smaldone A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643377
[TBL] [Abstract][Full Text] [Related]
4. Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease.
Smaldone A; Findley S; Bakken S; Matiz LA; Rosenthal SL; Jia H; Matos S; Manwani D; Green NS
Contemp Clin Trials; 2016 Jul; 49():134-42. PubMed ID: 27327779
[TBL] [Abstract][Full Text] [Related]
5. HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.
Smaldone A; Findley S; Manwani D; Jia H; Green NS
J Pediatr; 2018 Jun; 197():177-185.e2. PubMed ID: 29571930
[TBL] [Abstract][Full Text] [Related]
6. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
7. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use.
Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM
Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
10. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
[TBL] [Abstract][Full Text] [Related]
11. Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia.
Quinn CT; Niss O; Dong M; Pfeiffer A; Korpik J; Reynaud M; Bonar H; Kalfa TA; Smart LR; Malik P; Ware RE; Vinks AA; McGann PT
Br J Haematol; 2021 Aug; 194(3):617-625. PubMed ID: 34227124
[TBL] [Abstract][Full Text] [Related]
12. Adherence to hydroxyurea therapy in children with sickle cell anemia.
Thornburg CD; Calatroni A; Telen M; Kemper AR
J Pediatr; 2010 Mar; 156(3):415-9. PubMed ID: 19880135
[TBL] [Abstract][Full Text] [Related]
13. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896936
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
Charache S
Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
[TBL] [Abstract][Full Text] [Related]
16. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
17. Measuring hydroxyurea adherence by pharmacy and laboratory data compared with video observation in children with sickle cell disease.
Creary S; Chisolm D; Stanek J; Neville K; Garg U; Hankins JS; O'Brien SH
Pediatr Blood Cancer; 2020 Aug; 67(8):e28250. PubMed ID: 32386106
[TBL] [Abstract][Full Text] [Related]
18. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
Green NS; Barral S
Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
20. Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): Using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease.
Walden J; Brown L; Seiguer S; Munshaw K; Rausch J; Badawy S; McGann P; Winkler S; Gonzalez L; Creary S
PLoS One; 2024; 19(6):e0304644. PubMed ID: 38917111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
